# Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy

> **NCT07718737** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Multitude Therapeutics Inc.** · enrollment: 512 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)

## Interventions

- **DRUG:** AMT-116
- **DRUG:** Investigator's choice regimens (docetaxel or docetaxel plus ramucirumab)

## Key facts

- **NCT ID:** NCT07718737
- **Lead sponsor:** Multitude Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-28
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 512 (ESTIMATED)
- **Last updated:** 2026-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07718737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07718737, "Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07718737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*